Shares of Axsome Therapeutics Inc (NASDAQ:AXSM) rose 0.2% on Thursday after an insider bought additional shares in the company. The stock traded as high as $23.27 and last traded at $23.05. Approximately 63,564 shares were traded during trading, a decline of 97% from the average daily volume of 2,092,014 shares. The stock had previously closed at $23.00.

Specifically, Director Mark Coleman bought 4,650 shares of the company’s stock in a transaction that occurred on Monday, May 13th. The shares were purchased at an average cost of $21.44 per share, with a total value of $99,696.00. Following the transaction, the director now directly owns 652,648 shares of the company’s stock, valued at approximately $13,992,773.12. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Nick Pizzie bought 5,400 shares of the company’s stock in a transaction that occurred on Tuesday, March 19th. The stock was bought at an average cost of $12.58 per share, for a total transaction of $67,932.00. Following the completion of the transaction, the chief financial officer now directly owns 36,340 shares in the company, valued at $457,157.20. The disclosure for this purchase can be found here. Insiders bought a total of 15,150 shares of company stock worth $229,746 over the last 90 days. Company insiders own 27.50% of the company’s stock.

AXSM has been the topic of a number of recent analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of Axsome Therapeutics in a research report on Thursday, January 31st. Zacks Investment Research raised shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, February 5th. BidaskClub downgraded shares of Axsome Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Sunday, March 3rd. Finally, Cantor Fitzgerald raised their price objective on shares of Axsome Therapeutics from $13.00 to $16.00 and gave the stock an “overweight” rating in a research report on Friday, March 15th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $28.00.

The company has a market capitalization of $721.73 million, a P/E ratio of -20.06 and a beta of 3.54. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 3.86.

Axsome Therapeutics (NASDAQ:AXSM) last released its earnings results on Thursday, May 9th. The company reported ($0.32) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.01). On average, research analysts forecast that Axsome Therapeutics Inc will post -1.2 earnings per share for the current year.

Several hedge funds have recently added to or reduced their stakes in AXSM. Barclays PLC acquired a new stake in shares of Axsome Therapeutics in the 4th quarter worth $30,000. Ladenburg Thalmann Financial Services Inc. lifted its stake in shares of Axsome Therapeutics by 113.7% in the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,400 shares of the company’s stock worth $48,000 after acquiring an additional 1,809 shares during the period. Focused Wealth Management Inc acquired a new stake in shares of Axsome Therapeutics in the 1st quarter worth $64,000. Bank of New York Mellon Corp acquired a new stake in shares of Axsome Therapeutics in the 4th quarter worth $98,000. Finally, BlackRock Inc. lifted its stake in shares of Axsome Therapeutics by 14.6% in the 4th quarter. BlackRock Inc. now owns 64,049 shares of the company’s stock worth $181,000 after acquiring an additional 8,137 shares during the period. Institutional investors own 12.34% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Axsome Therapeutics (AXSM) Stock Price Up 0.2% on Insider Buying Activity” was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at https://www.dailypolitical.com/2019/05/16/axsome-therapeutics-axsm-stock-price-up-0-2-on-insider-buying-activity.html.

About Axsome Therapeutics (NASDAQ:AXSM)

Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the Phase III clinical trial for the treatment resistant depression; Phase II/III clinical trials in agitation associated with Alzheimer's disease; and Phase II clinical trial for the treatment of smoking cessation, as well as for major depressive disorder.

Featured Article: What Does a Sell-Side Analyst Rating Mean?

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.